ClinicalTrials.gg

Program

CEB-01

A development code. Also written as “CEB-01 membrane loaded with SN-38”.

Its studies are mostly in Pancreatic Neoplasms · Sarcoma, led by CEBIOTEX.

Furthest: phase 2, since May 15, 20253 company-led studies, 2 open or runningNext primary completion: Sep 2028 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CEBIOTEX32 open or runningphase 2since May 15, 2025Oct 30, 2020Sep 2028early phase 1 · NCT06538857

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2020First study: phase 1 study in SarcomaFirst studyNCT04619056 · 21 enrolled · Spain
  2. Aug 1, 2024Early phase 1 study in Pancreatic NeoplasmsNCT06538857 · 39 enrolled · Spain
  3. May 15, 2025Phase 2 study in Locally Resectable Pediatrics TumorsNCT06986811 · 80 enrolled · Spain

Ahead

  1. Sep 2028Primary completion: early phase 1 study in Pancreatic NeoplasmsNCT06538857
  2. May 2029Primary completion: phase 2 study in Locally Resectable Pediatrics TumorsNCT06986811

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06986811Locally Resectable Pediatrics Tumors · Spain2Active, not recruitingMay 202980
NCT06538857Pancreatic Neoplasms · SpainEarly 1Active, not recruitingSep 202839
NCT04619056Sarcoma · Spain1CompletedNov 28, 202521

How it is read

Names in the registry

  • “CEB-01”, 2 entries
  • “CEB-01 membrane loaded with SN-38”, 1 entry

Codes read as this program: CEB01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.